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Research Highlights 
 
 A new analog [G10a]SHa of temporin-SHa (FLSGIVGMLGKLFamide) was found 
to be cytotoxic to MCF-7, HeLa, H460, 3T3 cell lines. 
 The analog [G10a]SHa induced necrotic type of cell death in MCF7 cells. 
 By conjugating the analog [G10a]SHa to the breast cancer targeting peptide, a 
conjugate [G10a]SHa-BCTP selective for breast cancer cells was developed which 
acts by inducing apoptosis. 
  [G10a]SHa-BCTP up-regulated the caspase-3 and Bax expression, while down-
regulated the Bcl-2 and survivin, inducing programmed type of cell death in MCF7 
cells. 
 
ABSTRACT 
 
The frog natural product temporin-SHa (FLSGIVGMLGKLFamide) is a potent 
antimicrobial peptide, as is the analog [S3K]SHa. By solid-phase synthesis, we prepared 
temporin-SHa and several temporin-SHa analogs with one or more D-alanine residues 
incorporated. The natural product and the analog [G10a]SHa were found to be cytotoxic in 
mammalian cell lines and induce cell death. To achieve selectivity, we conjugated the 
analog [G10a]SHa with a breast cancer targeting peptide (BCTP). The resulting peptide 
temporin [G10a]SHa-BCTP conjugate was selectively active against the MCF-7 breast 
cancer cell line with no cytotoxicity in NIH-3T3 fibroblasts. Unlike the natural product or 
[G10a]SHa, the conjugated peptide induced apoptosis, down regulating the expression of 
Bcl-2 and survivin and up regulating Bax and  caspase-3. 
 
Abbreviations: AMP, Antimicrobial peptides; ANOVA, Analysis of Variance;  Bcl-2, B-
cell lymphoma 2 (Bcl-2), Bax, BCL2 Associated X; DMSO, Dimethyl sulfoxide; TFA, 
Trifluoroacetic acid; FACS, Fluorescence-activated cell sorting; GAPDH, Glyceraldehyde 
3-phosphate dehydrogenase; MCF-7, Michigan Cancer Foundation-7; MTT, 3-(4, 5-
Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; RPMI-1640 medium, Roswell 
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Park Memorial Institute (RPMI) 1640 Medium; SPSS, Statistical Package for the Social 
Sciences. 
 
Keywords: antimicrobial peptides, temporin-SHa analogs, breast cancer targeting peptide 
conjugate, apoptosis, Bcl-2, survivin, caspase-3  
 
1. Introduction 
Cancer is a condition that refers to abnormal cell growth with the potential to invade 
other parts of the body, and is one of the main causes of mortality 
worldwide. Conventional treatments include radiation or chemotherapy which often lack 
selectivity against cancer cells. The deleterious side effects on healthy cells and tissues 
cause toxicity towards vital organs and severe inflammatory responses due to necrosis [1-
4]. To improve the selectivity of therapeutic agents, one strategy involves conjugation of 
the cytotoxic drug with targeting ligands such as antibodies or tumor targeting peptides 
that recognize specific receptors on particular types of cancer cells [5-12]. Recently, a 
decapeptide sequence WXEAAYQXFL, with varied residues at X positions, was 
discovered to promote specific binding to breast cancer cell lines [10-12]. One of these 
breast cancer targeting peptides (BCTP), with D-norleucine and D-arginine residues in 
positions 2 and 8 respectively, was modified (r8k and C-terminal carboxyamidation) and 
then conjugated with the cytotoxic anticancer drug doxorubicin. The resulting conjugate 
exhibited selectivity for breast cancer cell lines compared to the parent drug [11]. 
We were interested in applying the cancer targeting concept to antimicrobial peptides 
(AMPs). Although AMPs are primarily known for their antimicrobial properties, some 
examples and their derivatives are reported as potent antitumor agents with low toxicity 
such as temporin-1CEa, ascaphin-8, alyteserin-2 and magainin-2 [13-17]. These AMPs 
bind to the plasma membrane and cause cell death by either necrosis or apoptosis [18-21]. 
As a proof of concept, we started with the antimicrobial peptide temporin-SHa 
(FLSGIVGMLGKLFamide). Temporin-SHa was isolated from the skin of the Sahara frog 
Pelophylax saharicus and reported as an antimicrobial agent active against bacteria, yeasts 
and fungi [22,23]. Temporin-SHa, the analogs temporin-[S3K]SHa and the L-alanine 
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substituted temporin-[A2,6,9]SHa  were not found cytotoxic against mammalian cell lines 
such as THP-1 monocytes (IC50>60 μM) and HepG2 cells (IC50 >600 μM) [23]. We 
synthesized various D-Ala substituted analogs of temporin-SHa and screened them against 
several cancer cell lines as well as 3T3 cells to identify analogs with anticancer activity. 
We then planned to conjugate the breast cancer targeting peptide (BCTP) [10-12] to the 
most potent analog to achieve selective targeting towards breast cancer.  
2. Materials and Methods 
2.1. General procedures 
Resins, amino acids, and coupling reagents, were procured from Novabiochem, and 
Chem-impex (USA). The 1H and 13C NMR spectra were recorded on Bruker NMR 
spectrometers (Bruker, Switzerland), operating at 600 MHz and 125 MHz, respectively. 
HRFAB-MS was recorded on JEOL JMS HX 110 mass spectrometers (Japan). All 
peptides were purified by using LC-908 W recycling preparative HPLC (Japan Analytical 
Industry) by using a Jaigel ODS-MAT 80 (C18) column. The purity of peptides was 
established by Ultra-Performance Liquid Chromatography (UPLC) (Agilent 1260 Infinity 
Diode Array, C-4 reversed-phase analytical column, 5μm, 150 x 4.6 mm). 
2.2. Peptide synthesis 
Solid-phase synthesis was performed manually by using a step-wise Fmoc peptide 
synthesis protocol. Rink amide MBHA resin (0.51 mmol/g, Novabiochem) soaked in 
DCM, was first treated with 20 % 4-methylpiperidine to remove the Fmoc protecting 
group from Rink linker. Fmoc-protected phenylalanine (3 equiv), Oxyma pure (0.65 g, 3 
equiv), and DIC (0.71 mL, 3 equiv) in 10 mL of DMF were added in the resin, and the 
suspension shaken overnight. Fmoc-phenylalanine loaded resin was then deprotected by 20 
% 4-methylpiperidine in DMF. The resin was then treated with the next Fmoc amino acid 
(3 equiv.) in DMF, Oxyma pure (3 equiv.) and DIC (3 equiv.). The reaction mixture was 
agitated for 2 hours. Completion of reaction was checked by a ninhydrin colorimetric test. 
Through repeated couplings, the synthesis of all peptide sequences and [G10a]SHa-BCTP 
conjugate (Scheme S1) was completed with removal of the Fmoc group on the last residue. 
The peptides were then cleaved from the resin with 95% TFA, cocktail (94 % TFA, 1 % 
triisopropylsilane, 2.5 % ethanedithiol, 2.5% water) for 2 hours at room temperature. The 
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crude peptide was precipitated with diethyl ether and recovered from centrifugation and 
then lyophilized. Further purification of peptides was carried out by RP-HPLC using 
acetonitrile / water (60:40) in 0.1 % TFA at a flow rate of 4 mL / min. 
 
 
2.3. Mass spectrometric analysis of peptides 
Matrix-assisted laser desorption/ionization (MALDI) analysis was performed on an 
Ultraflex III TOF/TOF (Bruker Daltonics, Bremen, Germany) mass spectrometer. All 
peptides, dissolved in H2O/ ACN (40:60), 0.1% TFA, were mixed with 0.5 μL of the 
matrix (HCCA) solution (saturated solution in 0.1% TFA/CH3CN, 2:1), and deposited on a 
MALDI plate. Spectra were recorded as described earlier [24]. ESI-QTOF-MS spectra 
were recorded on a Q-STAR XL mass spectrometer (Applied Biosystems). Each peptide 
dissolved in 0.1% TFA/H2O/ ACN 40:60 was infused directly into the mass spectrometer 
at a flow rate of 3 μL/min to acquire full scan and product ion mass spectra. The 
electrospray voltage at the spraying needle was optimized at 5500 V.  
2.4. Cell lines and materials  
NIH-3T3 (ATCC® CRL-1658™), NCI-H460 (ATCC® HTB-177™) and the human breast 
cancer cell line MCF-7 (ATCC® HTB-22™) were purchased from ATCC. MCF-7 cells were 
used because these cells retain many ideal characteristics particular of differentiated 
mammary epithelium. NCI-H460 cell line is derived from non-small cell lung carcinoma 
[25]. NIH-3T3 cells are mouse fibroblast cells suitable for transfection studies and can be 
used as a non-cancerous model for cytotoxicity studies [26]. DoHH2 cells were 1st isolated 
from pleural fluid of non-Hodgkin's lymphoma patient, act as representative of B-cell line 
(DoHH2) [27]. DoHH2 cells were kindly provided by Professor Daniel Hoessli from 
University of Geneva, Switzerland. HeLa cells were kindly donated by Dr. Anwar Siddiqui 
from Aga khan University Karachi, Pakistan. RPMI-1640 medium, FBS, and mouse anti-
human-Bcl-2 primary antibody and mouse anti-human beta-actin primary antibody were 
purchased from Sigma-Aldrich (USA). The TRIzol reagent and Alexa Fluor® 488goat 
anti-mouse secondary antibody were obtained from Invitrogen (USA). Anti-human-Bax 
primary antibody was procured from Santa Cruz Biotechnologies (USA). DAPI, TUNEL 
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Assay kit, cDNA synthesis kit and SYBR green master mix, and rabbit monoclonal anti-
survivin primary antibody were purchased from MP Biomedical (USA), Millipore-Merck 
(USA), Fermentas (USA), and Abcam (USA) respectively. 
 
 
2.5.  [3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] MTT assay 
The cytotoxic as well as antiproliferative effect of peptides was determined using 
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] colorimetric assay. 
Briefly MCF-7, NIH-3T3, HeLa, and NCI-H460 cells were cultured, and after confluency, 
cells were used to test the cytotoxicity. MTT, a tetrazolium salt, was used to check the 
cytotoxicity of cultured cells [28]. MTT became reduced when exposed to oxidoreductase 
in viable cells, and transformed into purple formazan crystals. Briefly 6000 of MCF-7 cells 
per well and 4000 cells of NIH-3T3, HeLa and NCI-H460 cells per well were seeded in 
96-wells plate and incubated at 37ºC in 5% CO2 for 24 h. MCF-7 cells were then treated 
with different doses of peptide [G10a]SHa  (12.5, 25 and 50 µM) and [G10a]SHa-BCTP 
(25, 50 and 100 µM) and re-incubated in 5% CO2 at 37ºC for 48 hours. The other cell lines 
were tested with different doses (1, 10 and 100 µM). Untreated control cells were treated 
with complete medium, while vehicle control cells with medium containing 0.5% DMSO. 
Doxorubicin, cycloheximide, and cisplatin were used as standard drugs for MCF-7, NIH-
3T3 and NCI-H460, respectively. After 48 hours, media containing compounds were 
removed and 200 µl medium containing (0.5 mg/ml) MTT was added to each well and re-
incubated for 4 h at 37 ºC in 5 % CO2. After 4 hours, MTT containing media were 
removed and formazan crystals were solubilised in pure DMSO and absorbance was 
measured using photometer (Thermofisher, USA) at 550 nm wavelength. Experiment was 
performed three times and all doses were repeated in triplicate and the calculations were 
done using formula for percent inhibition. 
Percent Inhibition = (Absorbance of control cells - Absorbance of treated cells) x100 
Absorbance of control cells 
2.6. Alamar blue assay 
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The viability of DoHH2 cells was determined by Alamar blue assay. Briefly cells 
were grown in RPMI media supplemented with 10% FBS and 1% penicillin/ streptomycin. 
Upon reaching confluence 20,000 cells per well were incubated with different 
concentrations (1, 10, and 100 µM) of compounds for 24 hrs. A one-tenth volume of 
Alamar blue was then added, and the incubation continued for 4 hrs. Absorbance was read 
in spectrophotometer at wavelengths of 570 nm and 600 nm [29]. 
2.7. DNA fragmentation assay  
DNA fragmentation occurs in the last stages of apoptosis. To assess the nature of cell 
death by [G10a]SHa and [G10a]SHa-BCTP conjugate, TUNEL assay was performed. 
2x106 cells MCF-7 cells were cultured in each well of 6-well plate and kept at 37°C 
overnight in 5% humidified CO2. Next day, seeded cells were treated with 0, 25, 50 and 
100 µM concentrations of [G10a]SHa and G10a]SHa-BCTP conjugate for 48 hrs. Then, 
cells fixation was done with 1% paraformaldehyde and kept in ice 60 minutes, and then 
centrifuged for 5 minutes at 3000 RCF. Cell pellets were washed in PBS and 50 µL of 
staining solution [containing reaction buffer, terminal deoxynucleotidyl transferase (TdT) 
enzyme, and deoxyuridine triphosphate labeled with fluorescein (F-dUTP)] added to the 
pellet and placed 37 °C for 90 minutes. After incubation, cells were rinsed to remove the 
stain, and PI/RNase solution was incubated with cells at 1 hour. Flow cytometric analysis 
was performed using FACSCaliburTM instrument. Readings were taken in triplicates for 
each sample. Initially, singlet cells were gated by excluding doublets. Main window was 
set as a dot plot having FL-2 filter (for PI) on X-axis and FL-1 filter (for FITC) on Y-axis. 
About 95% of total cells were gated on FSC/SSC dot plot and 10000 cells were counted 
during each analysis. Positive control cells used in experiment were provided in the by the 
manufacturer (Kit number APT110, Millipore-Merck). 
2.8. RNA isolation and complementary DNA synthesis 
The MCF-7 cells were seeded (1x106 cells/well) in 6-well plate, and kept in 5% CO2 
at 37ºC for overnight incubation. Next day, cells were treated with medium containing 0, 
25, 50, and 100 µM dose of [G10a]SHa-BCTP conjugate for 24 hrs. Total RNA was 
isolated using TRIzol reagent by following the manufacturer’s instructions. The isolated 
RNA was quantified and 260/280 ratios were calculated for RNA purity using 
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NANOdrop®. Agarose (1.2%) gel electrophoresis was run at 70 volts for 45 minutes to 
determine the integrity of RNA isolated. RNA samples (1000 ng) with good integrity were 
used to synthesize cDNA using RevertAid®first strand kit (ThermoScientific, USA). 
2.9. Gene expression analysis 
Real time gene expression analysis before and after treatment with [G10a]SHa-
BCTP conjugate was performed on Stratagene Mx3000p (Agilent Technologies, USA) 
using Maxima SYBR green (Fermentas, USA). Each reaction consisted of gene specific 
primers (1+1 µl), cDNA template (2 µl), nuclease free water (6 µl) and 2X SYBR master 
mix (10 µl). Table 1 shows the primer sequences used in this study. Bcl-2 and survivin 
were chosen as anti-apoptotic genes in this analysis, and Bax and caspase-3 as pro-
apoptotic genes. For the normalization of data, GAPDH was used as a reference gene. All 
the primers were designed to have the melting temperature between 55 to 60º C. Thermal-
cycling conditions were set as 95º C for 10 minutes (pre-denaturation, 1 cycle), 95º C for 
15 seconds, 60º C for 30 seconds, and 72º C for 30 seconds (40 cycles). Melting curve 
temperatures were 95º C, 60ºC and 95º C for 14 seconds each. At the end of each extension 
cycle, SYBR green signals were detected, and converted automatically into ct-values. Fold 
change was calculated manually by using ∆∆ct method: 
Fold change = 2-∆∆ct 
Where ∆∆ct = [ct of treated sample for gene of interest – ct of untreated sample for gene of 
interest] – [ct of treated sample for GAPDH - ct of untreated sample for GAPDH] 
2.10. Immunocytochemistry  
To confirm the gene expression analysis results, change in Bax, Bcl-2, survivin and 
beta-actin protein expression after [G10a]SHa-BCTP treatments was checked by 
immunocytochemistry, using a fluorescence microscope (Nikon-90i, Japan) coupled with 
NIS-Element Software (Nikon, Japan). Chambered slides were used to culture MCF-7 cells 
at a density of 4 x 104 cells/well. Next day, cells were incubated with 25, 50 and 100 µM 
doses for 48 hours. Control cells were incubated with medium only. Then, cells were 
washed with PBS twice and fixed with paraformaldehyde (1%) for 30 Minutes. Triton-
X100 (0.5%) was used to increase the cellular membrane permeabilization for 5 minutes. 
Blocking was done for 10 minutes with ROTI® reagent (Carl Roth, Germany). Cells were 
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incubated for 90 minutes with their respective primary monoclonal antibodies (1:200 
dilutions). Subsequently, cells were incubated with Alexa Fluor-488 conjugated secondary 
antibodies (1:200 dilutions) for 45 minutes. A set of control and treated cells were also 
stained with DAPI instead of antibodies. Slides were washed twice with PBS and then 
mounted. Images were taken using green and blue channels under 20 x lens (200x of 
original size).  
2.11. Statistical analysis. 
The data were statistically analyzed using SPSS and Microsoft Excel. Mean and 
standard deviation were calculated from three replicates for MTT assay, real time PCR and 
ImageJ readings as representatives of data. One-way ANOVA with Tukey’s test was 
utilized to determine p-values for the significance of data. 
 
3. Results and Discussion 
3.1. Synthesis 
Temporin-SHa (FLSGIVGMLGKLFamide) and its analog [S3K]SHa are reported as 
potent antimicrobial peptides, while L-alanine-substituted analogs of SHa lack antibacterial 
and antiparasitic activities. A study regarding the antiparasitic activity of temporin-SHa 
revealed apoptotic cell death in Leishmania infantum [23]. To date, no anticancer activity 
of temporin-SHa or any of its analogs is reported. 
Partial or entire D-amino acid substitution is reported as a useful approach to 
develop better therapeutic activities, to increase the resistance to proteolysis and to 
overcome many hurdles faced by host defense peptides [30, 31]. In the current study, the 
stereochemically more flexible achiral glycine residues at positions 4, 7 and/or 10 of 
temporin-SHa, were substituted with D-Ala residues to obtain several analogs [G4a]SHa, 
[G7a]SHa, [G10a]SHa, [G4,7a]SHa, [G4,7,10a]SHa, and [G7,10a]SHa (Table 2) through 
Fmoc solid-phase synthesis [31,32]. The identity was assessed by matrix-assisted laser 
desorption/ionization-time of flight (MALDI-TOF) mass spectrometry, HR-MALDI-TOF-
MS, MALDI/MS/MS and NMR studies (Fig. S1-S16, Table S1-S9). 
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3.2. [G10a]SHa-BCTP showed affinity and selectivity for MCF-7 cells 
Many antimicrobial peptides were reported to possess anticancer activities. However, 
the antimicrobial peptide temporin-SHa was reported as non-cytotoxic against the HepG2 
cell line [23]. We decided to perform anticancer screening of temporin-SHa and its analogs 
(Table 2) against different cancer cell lines as well as NIH-3T3 murine fibroblast cell line 
(Table 3). Interestingly, the natural product temporin-SHa was found active against MCF-
7, HeLa, and NCI-H460 cell lines with no cytotoxicity against DoHH2 cell line. The 
analog [G10a]SHa containing D-alanine in place of glycine at position 10 was found to be 
the most cytotoxic against MCF-7, HeLa and NCI-H460 cells among the peptides 
synthesized. Since it was cytotoxic to normal NIH-3T3 murine fibroblast cell line, we 
decided to improve selectivity by conjugating this peptide with the breast cancer targeting 
peptide (BCTP) ligand (WLEAAYQKFL) (Scheme S1), which afforded [G10a]SHa-BCTP 
conjugate (Fig. 1).   
The [G10a]SHa-BCTP conjugate was fully characterized by mass spectrometry 
(Table 2) and NMR studies (Fig. S16, Table S9). The cytotoxicity of the native peptide 
[G10a]SHa and [G10a]SHa-BCTP conjugate was checked against MCF-7 cells at different 
doses (Fig. 2). In contrast to the native peptide [G10a]SHa, the conjugate [G10a]SHa-
BCTP was active against the MCF-7 breast cancer cell line without cytotoxicity against 
non-cancerous cells as indicated by MTT assay results for mouse fibroblast cell line 
(Table 3). By using the reported cell-growth on-bead assay [33], we established that this 
peptide showed strong binding to MCF-7 cells (Fig. S17). Further studies were carried out 
to understand the mechanism for the increased specificity of [G10a]SHa-BCTP for MCF-7 
cells. 
 
 
 
 
3.3. DNA fragmentation assay  
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Nature of cell death induced by peptides ([G10a]SHa and [G10a]SHa-BCTP conjugate 
was analyzed by DNA fragmentation using standard TUNEL assay to differentiate 
between apoptosis and necrosis (Fig. 3). Cultured MCF-7 cells were treated with 0, 25, 50, 
and 100 µM of [G10a]SHa and [G10a]SHa-BCTP conjugate for 48 hours. The [G10a]SHa 
treated cells demonstrated extremely low level of DNA fragmentation, as indicated by low 
fluorescein labeling at all doses (Fig. 3C, 3E and 3G). However, intense fluorescence 
signals were observed for [G10a]SHa-BCTP conjugate at 25, 50 and 100 µM, thus 
indicating highly fragmented DNA (Fig. 3D, 3F and 3H) and the dot plot pattern was 
similar to that of the positive control cells (Fig. 3A).  
From these observations, it can be concluded that [G10a]SHa peptide induced cell death 
via necrosis, whereas the [G10a]SHa-BCTP conjugate triggered apoptotic cell death in a 
dose-dependent manner. It is proposed that BCTP ligand facilitated receptor mediated 
delivery of [G10a]SHa-BCTP conjugate to breast cancer cells. The switching from 
necrosis to apoptosis may be due to the internalization of [G10a]SHa-BCTP conjugate, 
resulting in the delivery of peptide [G10a]SHa inside the cell to ultimately cause the 
induction of apoptosis.  
3.4. Expression of pro- and anti-apoptotic genes following treatment with 
[G10a]SHa-BCTP conjugate  
The results obtained from TUNEL assay indicated the apoptotic type of cell death 
by [G10a]SHa-BCTP conjugate and further molecular studies were performed with this 
peptide. Modulation in pro- and anti-apoptotic gene expression (including Bax, Bcl-2, 
caspase-3 and survivin) was evaluated using real time PCR after treatment with 
[G10a]SHa-BCTP conjugate for 24 hours. GAPDH gene expression was checked as a 
reference gene to normalize the data for each cDNA sample. Immunocytochemistry was 
performed to confirm the results at translational level. 
Regulation of apoptosis is achieved by several types of proteins in a well 
programmed manner. Among these regulatory proteins, Bcl-2 family plays its critical role. 
This family includes various pro- and anti-apoptotic factors, working in a strong co-
ordination in response to intra- and extracellular environmental factors. Various peptides 
have been studied for their impact on Bcl-2 expression in human cancer cells. Bufalin, a 
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peptide, has shown inhibition of ovarian tumor cells growth by down regulating Bcl-2 gene 
expression and Bax up-regulation [34]. In another report, a bioactive peptide, Chan Su, 
isolated from amphibian skin increased the expression of Bax protein and decreased Bcl-2 
expression, thus resulting in apoptotic cell death [35]. In this study, the expression of Bcl-2 
mRNA has been decreased significantly by [G10a]SHa-BCTP conjugate in MCF-7 cells 
(Fig. 4).This decrease in Bcl-2 expression was dose-dependent that is 0.7 and 0.6 folds at 
50 and 100 µM doses, respectively. Immunocytochemistry images showed similar pattern 
for Bcl-2 protein expression as that was obtained at mRNA level (Fig. 5). Bcl-2 protein 
maintains the mitochondrial membrane integrity, prevent the release of cytochrome c in 
cytoplasm that ultimately inhibit the apoptosis to occur [36-37]. Bcl-2 protein also blocks 
the activity of Bak and Bax proteins (both are apoptotic) by preventing their 
oligomerization. Bcl-2 can inhibit both type of apoptotic pathways either apoptosome 
dependent or independent [38]. 
Few anticancer peptides have been reported for their effect on Bax protein 
expression [39-40]. Results obtained from gene expression analysis of Bax with 
[G10a]SHa-BCTP conjugate treatment showed the significant decrease in Bax gene 
expression that was down to 0.88, 0.75 and 0.74 folds of untreated control cells at 25, 50 
and 100 µM doses, respectively (Fig. 6). Since we have observed significant increase in 
Bax gene expression after [G10a]SHa-BCTP conjugate treatment, therefore, Bax / Bcl-2 
ratio was calculated for all doses (Table 4). These ratios become increased at 50 and 100 
µM doses due to more decrease in Bcl-2 gene expression. However, fluorescence 
microscope images for Bax expression showed significant increase in Bax protein 
expression (Fig. 7). Immunofluorescence images of MCF-7 cells for Bax protein indicate 
the increase at 25 and 50 µM dose after [G10a]SHa-BCTP conjugate treatment. However, 
at higher doses of 100 µM dose, Bax protein expression became limited to few spots due to 
48 hour treatment time. From these observations at mRNA and protein levels, it can be 
concluded that after [G10a]SHa-BCTP conjugate treatment, decrease in Bax gene 
expression might be overcome by more decrease in Bcl-2 gene expression resulting in the 
favorable conditions that induce apoptosis or it can be proposed that [G10a]SHa-BCTP 
conjugate regulates the Bax expression after transcription. Another proposed mechanism is 
the release of Bax protein from other protein complexes or cellular structures after 
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[G10a]SHa-BCTP conjugate treatment. Bax is a monomeric protein and its expression 
induces apoptosis in cancer cells. It resides in cytosolic part normally while in apoptosis, it 
becomes attached with outer mitochondrial membrane and form pores in it that ultimately 
releases the several factors like cytochrome c and others. 
 
 
 
Inhibitors of apoptosis (IAPs) are also involved in regulation of apoptosis. Survivin, an 
IAP, plays its role in cell division cycle in tumor cells [41]. Previous studies regarding 
survivin expression after peptides treatment showed that down regulation of survivin 
induce programmed cell death [42-43]. In current study, [G10a]SHa-BCTP conjugate 
down regulated the survivin expression when compared with control cells. At 25 µM 
concentration, no change was observed (Fig. 8). However, at 50 and 100 µM doses, 
survivin expression decreased significantly down to 0.7 folds of control cells. Similarly, 
survivin protein expression also decreased showing a good correlation with mRNA levels. 
Micrographs for survivin showed the change in its arrangement with decrease in its 
expression after treatment with [G10a]SHa-BCTP conjugate (Fig. 9). In untreated control 
cells, survivin protein were located near the cell membrane. However, in 25 and 50 µM 
treated cells, expression of survivin decreased. Interestingly, at 100 µM dose, due to cell 
shrinkage survivin molecules aggregate together. This decrease in mRNA and protein 
expression clearly indicates that survivin down regulation is involved in programmed cell 
death at transcription as well as translation levels. Survivin exhibits its function through 
both extrinsic and intrinsic pathway of apoptosis (at the convergence point) and activates 
the caspase-3 and -7 [44]. 
 
 
 
Caspases play their critical role in apoptosis, as they activate main catalytic enzymes 
required for programmed cell death. Caspase-3 is the most important among all caspases. 
Previous studies about the effect of AMPs using solid tumor cells showed caspase-3 
activation resulting in apoptotic cell death [17, 45]. Similarly, in this study, [G10a]SHa-
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BCTP conjugate up-regulated the caspase-3 gene expression upto 4 to 5 folds in 
comparison with untreated control cells in MCF-7 cells (Fig. 10). This increase in caspase-
3 expression is also supported by fluorescence micrographs for nuclear staining (DAPI) 
after treatment with [G10a]SHa-BCTP conjugate. These images indicate with increasing 
dose, decrease in cell number, nuclear condensation and formation of apoptotic bodies 
(Fig. 11). Being an important constituent of cytoskeleton and one of the main substrate of 
caspases, -actin protein pattern and arrangement was also checked. Images for treated 
cells deterioration of cytoskeleton structure at higher doses that was intact in control cells 
image (Fig. 12). This destruction of -actin protein structure, formation of apoptotic bodies 
and caspase-3 up-regulation validate the results obtained from TUNEL assay and confirms 
apoptosis induction. Caspase-3 plays its role as an executioner enzyme of caspase cascade 
(both extrinsic and intrinsic pathway) and further activates proteases and endonucleases. 
Endonucleases cut the nuclear material into short 180 bp fragments and proteases catalyze 
the actin structure, both helping in the formation of small apoptotic bodies. 
 
 
4. Conclusions 
By solid phase peptide synthesis, we prepared the frog antimicrobial peptide temporin-
SHa and a series of analogs by replacing one or more glycine residues by D-alanine to 
improve peptide stability. Although the antimicrobial properties of temporin-SHa are well 
documented, we discovered that the natural peptide and analogs are inhibitors of human 
cancer cell lines in micromolar concentration. The highest activity was observed with 
[G10a]SHa and we conjugated this peptide with a breast cancer targeting peptide (BCTP) 
to improve selectivity. The temporin-BCTP conjugate was found to be a selective inhibitor 
of MCF-7 breast cancer cells. Further investigation of the mechanism revealed the 
conjugate induced apoptosis in MCF-7 cells through the up-regulation of caspase-3 
expression and the inhibition of anti-apoptotic gene expression. Thus, conjugation to the 
breast cancer targeting peptide not only significantly improved the selectivity of 
[G10a]SHa but also switched the mechanism of cell death. 
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Figures captions 
 
 
 
Fig. 1. Structure of [G10a]SHa-BCTP conjugate. 
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AC
CE
PT
ED
 M
AN
US
CR
IPT
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Fig. 2. Cytotoxicity of [G10a]SHa peptides against MCF-7 breast cancer cells. Fig. 2A shows 
cytotoxicity of [G10a]SHa, while Fig. 2B shows the cytotoxicity of the [G10a]SHa-BCTP conjugate. 
Data are represented as a mean of triplicates for each dose ± S.D. The concentration of DMSO used was 
0.5% as it was the amount used to dissolve the highest dose of [G10a]SHa-BCTP conjugate (100 µM). 
One-way ANOVA reveals significant difference i.e., *p < 0.05, **p < 0.01 and ***p < 0.001 in 
comparison with control cells. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
Fig. 3. TUNEL assay for [G10a]SHa and [G10a]SHa-BCTP conjugate. [G10a]SHa found to be 
necrotic for MCF-7 cells in Fig. 3c, 3e and 3g (25, 50 and 100 µM doses of [G10a]SHa, respectively). 
On the other hand, intense DNA fragmentation after [G10a]SHa-BCTP conjugate treatment showed 
apoptotic cell death (Fig. 3D, 3F and 3H showing 25, 50 and 100 µM doses of [G10a]SHa-BCTP 
conjugate , respectively). Fig. 3A represents the positive control cells. Control cells were treated with 
complete medium (Fig. 3B). Total 95% cells were gated and 10000 cells were counted for each case. 
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Fig. 4. Bcl-2 gene expression in [G10a]SHa-BCTP treated MCF-7 cells. RT-PCR was performed for Bcl-2 
gene in triplicate for all doses and data was normalized using GAPDH. Cells incubated with complete 
medium only are represented by the bar labelled as Control. Data represents the mean of triplicates ± 
Standard deviation. One-way ANOVA was used for significant difference (i.e. * denotes p-value less 0.05, 
** denotes p-value less 0.01 and *** denotes p-value less 0.001) when comparing treated samples with 
control cells. 
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 (E) 
Fig. 5. Bcl-2 expression in [G10a]SHa-BCTP treated MCF-7 cells. (A) Untreated control cells; (B, C 
and D) Cells treated with 25, 50 and 100 µM of [G10a]SHa-BCTP conjugate. Cells were then fixed, 
incubated with Bcl-2 primary/secondary antibodies and images were taken using fluorescence 
microscope (Nikon 90i microscope). Image J software was used to quantify the intensity of 
fluorescence light produced by images (Fig. E). 
 
 
Fig. 6. Bax gene expression in [G10a]SHa-BCTP treated MCF-7 cells. RT-PCR was performed for Bax gene 
in triplicate for all doses and data was normalized using GAPDH. Cells incubated with complete medium 
only are represented by the bar labeled as Control. Data represents the mean of triplicates ± Standard 
deviation. One-way ANOVA was used for significant difference (i.e. * denotes p-value less 0.05, ** denotes 
p-value less 0.01 and *** denotes p-value less 0.001) when comparing treated samples with control cells. 
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 (E) 
Fig. 7. Bax expression in [G10a]SHa-BCTP treated MCF-7 cells. (A) Untreated control cells; (B, C and 
D) Cells treated with 25, 50 and 100 µM of [G10a]SHa-BCTP conjugate. Cells were then fixed, 
incubated with Bax primary/secondary antibodies and images were taken using fluorescence 
microscope (Nikon 90i microscope). Image J software was used to quantify the intensity of 
fluorescence light produced by images (Fig. E). 
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Fig. 8. Gene Expression of survivin in [G10a]SHa-BCTP treated MCF-7 cells. RT-PCR was performed for 
survivin gene in triplicate for all doses and data was normalized using GAPDH. Cells incubated with 
complete medium only are represented by the bar labelled as Control. Data represents the mean of triplicates 
± Standard deviation. One-way ANOVA was used for significant difference (i.e. * denotes p-value less 0.05, 
** denotes p-value less 0.01 and *** denotes p-value less 0.001) when comparing treated samples with 
control cells. 
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 (E) 
Fig. 9. Survivin expression in [G10a]SHa-BCTP treated MCF-7 cells. (A) Untreated control cells; (B, 
C and D) Cells treated with 25, 50 and 100 µM of [G10a]SHa-BCTP conjugate. Cells were then fixed, 
incubated with survivin primary/secondary antibodies and images were taken using fluorescence 
microscope (Nikon 90i microscope). ImageJ software was used to quantify the intensity of fluorescence 
light produced by images (Fig. E). 
 
 
 
Fig. 10. Caspase-3 gene expression in [G10a]SHa-BCTP treated MCF-7 cells. RT-PCR was performed for 
caspase-3 gene in triplicate for all doses and data was normalized using GAPDH. Cells incubated with 
complete medium only are represented by the bar labeled as Control. Data represents the mean of triplicates 
± Standard deviation. One-way ANOVA was used for significant difference (i.e. * denotes p-value less 0.05, 
** denotes p-value less 0.01 and *** denotes p-value less 0.001) when comparing treated samples with 
control cells. 
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Fig. 11. Nuclear staining of [G10a]SHa-BCTP treated MCF-7 cells with DAPI. (A) Untreated control 
cells; (B, C and D) Cells treated with 25, 50 and 100 µM of [G10a]SHa-BCTP conjugate. Cells were 
then fixed, stained with DAPI and images taken using fluorescence microscope (Nikon 90i 
microscope). Condensation of nuclear material and formation of smaller apoptotic bodies are indicated 
by arrow heads. Image J software was used to quantify the intensity of fluorescence light produced by 
images (Fig. E). 
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 (E) 
Fig. 12. β-actin expression in [G10a]SHa-BCTP treated MCF-7 cells. (A) Untreated control cells; (B, C 
and D) Cells treated with 25, 50 and 100 µM of [G10a]SHa-BCTP conjugate. Cells were then fixed, 
incubated with β-actin primary/secondary antibodies and images were taken using fluorescence C 
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microscope (Nikon 90i microscope). Image J software was used to quantify the intensity of 
fluorescence light produced by images (Fig. E). 
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Table 
 
Table 1 
List of primers 
S. No Primer  Left Right 
1 Bcl-2 5´-gaggattgtggccttctttg-3´ 5´-acagttccacaaaggcatcc-3´ 
2 Caspase-3 5´-atggaagcgaatcaatggac-3´ 5´-atcacgcatcaattccacaa-3´ 
3 Bax 5´-agatcatgaagacaggggcc-3´ 5´-gcaatcatcctctgcagctc-3´ 
4 Survivin 5´-cagagtccctggctcctctac-3´ 5´-ggctcactgggcctgtcta-3´ 
5 GAPDH 5´-ccagaacatcatccctgcct-3´ 5´-cctgcttcaccaccttcttg-3´ 
 
Table 2  
Characterization Data of peptides  
No.  Mol. Formula Obs. 
mass 
 
Calc. 
Mass 
HRMS   Overall 
Yield (%) 
1 Temporin-SHa Phe
1-Leu2-Ser3-Gly4-Ile5-Val6-Gly7-Met8-Leu9-
Gly10-Lys11-Leu12-Phe13-NH2 
[M+Na]+ 
1402.8 
1402.789 1402.789 37.0 
2 [G4a]SHa Phe
1-Leu2-Ser3-D-Ala4-Ile5-Val6-Gly7-Met8-Leu9-
Gly10-Lys11-Leu12-Phe13-NH2 
[M+Na]+ 
1416.8 
1416.805 1416.804 68.5 
3 [G7a]SHa Phe
1-Leu2-Ser3-Gly4-Ile5-Val6- D-Ala7-Met8-Leu9-
Gly10-Lys11-Leu12-Phe13-NH2 
[M+Na]+ 
1416.9 
1416.805 1416.808 69.6 
4 [G10a]SHa Phe
1-Leu2-Ser3-Gly4-Ile5-Val6-Gly7-Met8-Leu9- D-
Ala10-Lys11-Leu12-Phe13-NH2 
[M+H]+ 
1394.9 
1394.823 1394.822 81.6 
5 [G4,7a]SHa Phe
1-Leu2-Ser3- D-Ala4-Ile5-Val6- D-Ala7-Met8-
Leu9-Gly10-Lys11-Leu12-Phe13-NH2 
[M+Na]+ 
1430.8 
1430.820 1430.820 80.2 
6 [G4,7,10a]SHa Phe
1-Leu2-Ser3- D-Ala4-Ile5-Val6- D-Ala7-Met8-
Leu9- D-Ala10-Lys11-Leu12-Phe13-NH2 
[M+Na]+ 
1444.8 
1444.836 1444.836 27.9 
7 [G7,10a]SHa Phe
1-Leu2-Ser3-Gly4-Ile5-Val6- D-Ala7-Met8-Leu9-
D-Ala10-Lys11-Leu12-Phe13-NH2 
[M+Na]+ 
1430.83 
1430.820 1430.820 37.7 
8 [G10a]SHa-
BCTP  
conjugate 
Phe1-Leu2-Ser3-Gly4-Ile5-Val6-Gly7-Met8-Leu9- D-
Ala10-Lys11-Leu12-Phe13-NH2 
 
Phe15-Leu14 
Trp23-Leu22-Glu21-Ala20-Ala19-Tyr18-Gln17-Lys16- 
 
[M+Na]+ 
2666.5 
2666.454 
 
 
2666.454 22.1 
Note: capital letters showing L amino acids and small letters are representatives of D configuration.  
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Table 3  
Cytotoxicity studies of temporin-SHa analogs and [G10a]SHa-BCTP conjugate (IC50 in µM) 
No. NIH-3T3 MCF-7 HeLa NCI-H460 DoHH2 
Temporin-SHa 73.3 ± 0.007 14.47 ± 0.57 18.36 ± 0.92 34.5 ± 1.5 >100 
[G4a]SHa >100 17.9 ± 1.1 >100 >100 >100 
[G7a]SHa >100 22.4 ± 2.2 >100 >100 >100 
[G10a]SHa 16.02 ± 3.7 16.2 ± 2.2 22.7 ± 0.86 24.3 ± 0.8 >100 
[G4,7a]SHa >100 29.5 ± 6.03 >100 37.3 ± 3.5 >100 
[G4,7,10a]SHa >100 26.33 ± 5.8 >100 >100 >100 
[G7,10a]SHa 7.5 ± 0.03 21.3 ± 1.13 >100 >100 >100 
[G10a]SHa-BCTP 
conjugate 
>100 26.85 ± 1.85 >100 >100 >100 
Cycloheximide 0.46 ± 0.07 - - - - 
Doxorubicin - 1.6 ± 0.2 5.7 ± 0.36 - - 
Cisplatin - - - 10.3 ± 0.6 - 
Imatinib - - - - 42.5 ± 3.5 
 
Table 4 
Ratio of Bax/Bcl-2 in MCF-7 cells treated with [G10a]SHa-BCTP conjugate at 25, 50 and 
100 µM doses 
  Bax (Mean ± St. Dev) Bcl-2 (Mean ± St. Dev) Bax /Bcl-2 
Control 1.00 ± 0.04 1.00 ± 0.11 0.99 
25 µM  0.88 ± 0.06 1.20 ± 0.08 0.73 
50 µM  0.75 ± 0.01 0.63 ± 0.11 1.20 
100 µM  0.74 ± 0.03 0.57 ± 0.17 1.30 
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